Integrated Stepped Care for Unhealthy Alcohol Use in HIV

Sponsor
Yale University (Other)
Overall Status
Completed
CT.gov ID
NCT01410123
Collaborator
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (NIH), US Department of Veterans Affairs (U.S. Fed)
319
5
2
67.9
63.8
0.9

Study Details

Study Description

Brief Summary

The study is a series of 3 linked randomized clinical trials of 6 month duration, with a total of 12 month follow-up, to evaluate the effect of Integrated Stepped Care on drinking outcomes and HIV biologic markers (including VACS index) in HIV-infected patients with unhealthy alcohol use.

Condition or Disease Intervention/Treatment Phase
  • Other: Integrated Stepped Care (ISC)
  • Other: Treatment as Usual
N/A

Detailed Description

Unhealthy alcohol use threatens the health benefits seen with antiretroviral therapy (ART) for HIV-infected (HIV+) patients. Although research has demonstrated the efficacy of brief interventions, motivational counseling, and medications to treat unhealthy alcohol use in HIV uninfected patients, there is limited research or use of these treatments in HIV+ patients. We have demonstrated that integrated treatment of addiction in HIV clinics is feasible. Stepped care algorithms can facilitate the evaluation of varying intensities of treatments for unhealthy alcohol use. The proposed study will compare onsite Integrated Stepped Care treatment (ISC) to treatment as usual (TAU) in three, linked, 6-month randomized clinical trials in 642 HIV+ patients with unhealthy alcohol use. Screened patients are randomized to ISC or TAU after determining that they meet criteria for either 1) at-risk drinking, 2) alcohol abuse or dependence or 3) moderate alcohol consumption in the presence of liver disease. ISC and TAU are tailored to the drinking category. ISC for at-risk drinkers and those with Moderate Alcohol use and Liver Disease begins with a brief intervention and is stepped up to Motivational Enhancement Therapy (MET) in those who meet predefined failure criteria. ISC for abuse or dependence begins with addiction physician management (APM) including alcohol pharmacotherapy if not contraindicated. APM is stepped up to include MET if predefined failure criteria are met. The study will test the hypothesis that ISC leads to decreased alcohol consumption and improved HIV biomarkers. Data analyses will be conducted on the intention to treat sample.

Study Design

Study Type:
Interventional
Actual Enrollment :
319 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Integrated Stepped Care for Unhealthy Alcohol Use in HIV
Study Start Date :
Jan 1, 2013
Actual Primary Completion Date :
Jul 31, 2018
Actual Study Completion Date :
Aug 31, 2018

Arms and Interventions

Arm Intervention/Treatment
Other: Treatment as Usual (TAU)

Other: Treatment as Usual
The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.

Other: Integrated Stepped Care (ISC)

Other: Integrated Stepped Care (ISC)
At risk drinking: Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy Alcohol abuse/dependence: Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare Moderate Alcohol + Liver Disease: Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy.

Outcome Measures

Primary Outcome Measures

  1. At risk drinking: Drinks per week [6 months]

  2. Alcohol abuse or dependence: Drinks per week [6 months]

  3. Moderate Alcohol + Liver Disease group: Abstinence. [6 months]

Secondary Outcome Measures

  1. Alcohol consumption by phosphatidylethanol (PEth), an alcohol biomarker [6 months]

  2. Change in biological markers as measured by the VACS index. [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Be HIV-infected and receiving HIV care at one of the participating medical centers.

  2. Meet one of the following criteria for unhealthy alcohol use:

  • At-risk Drinking Study- greater than 14 drinks per week or greater than 4 drinks per occasion in men and greater than 7 drinks per week or greater than 3 drinks per occasion in women and those over 65.

  • Alcohol Abuse or Dependence Study - Meet DSM-IV TR criteria for alcohol abuse or dependence, not in remission.

  • Moderate Alcohol + Liver Disease Study - Report alcohol consumption in the past month, are HCV co-infected, confirmed by HCV viral load or have liver fibrosis - Fib-4 (>1.45). Do not meet criteria for at-risk drinking, alcohol abuse or dependence.

  1. Be able to understand English and provide informed consent.
Exclusion Criteria:
  1. Be acutely suicidal, or with a psychiatric condition that affects the ability to provide informed consent or participate in counseling interventions (e.g. psychotic, dementia, delusional).

  2. Be currently enrolled in formal treatment for alcohol (excluding self-help, e.g. Alcoholics Anonymous)

  3. Have medical conditions that would preclude completing or be of harm during the course of the study.

  4. Pregnant or nursing women or women who do not agree to use a reliable form of birth control.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Washington DC VAMC Washington District of Columbia United States 20422
2 VAMC Atlanta Atlanta Georgia United States 30033
3 New York VAMC - New York Harbor Healthcare System New York New York United States 10010
4 Dallas VA Medical Center Dallas Texas United States 75216
5 VAMC Houston Houston Texas United States 77030

Sponsors and Collaborators

  • Yale University
  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)
  • US Department of Veterans Affairs

Investigators

  • Principal Investigator: David Fiellin, MD, Yale University
  • Study Director: Jennifer Edelman, M.D., MHS, Yale University

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Yale University
ClinicalTrials.gov Identifier:
NCT01410123
Other Study ID Numbers:
  • 1105008544
  • U01AA020795
First Posted:
Aug 4, 2011
Last Update Posted:
Nov 9, 2020
Last Verified:
Nov 1, 2020

Study Results

No Results Posted as of Nov 9, 2020